Tealwood Asset Management Inc. has significantly increased its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT), purchasing an additional 11,433 shares during the third quarter of 2023. This acquisition lifted Tealwood’s holdings in the biotechnology firm by 58%, bringing its total ownership to 31,156 shares. As of the latest filing with the Securities and Exchange Commission, the value of these shares stands at approximately $2,589,000.
Several other institutional investors have also adjusted their positions in Corcept Therapeutics recently. Golden State Wealth Management LLC acquired a new stake in the company valued at around $28,000 during the second quarter. Meanwhile, Huntington National Bank raised its stake by 54%, now owning 479 shares valued at $35,000. Other notable increases include Employees Retirement System of Texas and USA Financial Formulas, which acquired new positions valued at $52,000 and $56,000, respectively. Farther Finance Advisors LLC made a significant move, increasing its stake by 277.6% and now holding 910 shares worth $67,000. Institutional investors currently own 93.61% of Corcept’s stock.
Corcept Therapeutics’ Market Performance
As of Friday, Corcept Therapeutics’ shares opened at $82.65. The company has experienced a 52-week low of $49.00 and a high of $117.33. With a market capitalization of $8.69 billion, Corcept’s financial stability is reflected in its low debt-to-equity ratio of 0.01, a quick ratio of 3.07, and a current ratio of 3.14. The firm’s 50-day moving average price is $78.76, while the 200-day moving average stands at $75.49. The price-to-earnings ratio is reported at 93.92, with a beta of 0.20, indicating low volatility compared to the market.
In recent insider activities, CEO Joseph K. Belanoff sold 40,000 shares on December 1, 2023, at an average price of $79.77, totaling approximately $3,190,800. Following this transaction, Belanoff retains 2,701,370 shares valued at around $215,488,284.90, reflecting a 1.46% decrease in his ownership. Additionally, insider Sean Maduck sold 20,000 shares for approximately $1,590,400, resulting in a position of 7,904 shares valued at $628,526.08.
Analyst Ratings and Company Overview
Various analysts have provided insights into Corcept Therapeutics’ market position. Canaccord Genuity Group reiterated a “buy” rating with a price objective of $140.00. UBS Group initiated coverage with a “neutral” rating and a price target of $95.00. Wolfe Research assigned a “peer perform” rating, while Zacks Research upgraded the company from a “strong sell” to a “hold” rating. Overall, four analysts have rated the stock as a “buy,” and four have issued “hold” ratings, indicating a consensus on a “Moderate Buy” outlook with an average price target of $127.20.
Corcept Therapeutics, based in the United States, is a clinical-stage biopharmaceutical company dedicated to developing drugs that modulate cortisol effects. The company aims to address significant unmet medical needs related to severe metabolic, oncologic, and psychiatric disorders. Its flagship product, Korlym (mifepristone), is approved for treating hyperglycemia secondary to Cushing’s syndrome in patients with type 2 diabetes or glucose intolerance who are not candidates for surgery.
For more detailed updates and financial information on Corcept Therapeutics, stakeholders can visit HoldingsChannel.com for the latest 13F filings and insider trades.
